



lovance Biotherapeutics to Present at Two Upcoming September Conferences

September 5, 2017

SAN CARLOS, Calif., Sept. 05, 2017 (GLOBE NEWSWIRE) -- lovance Biotherapeutics, Inc. (NASDAQ:IOVA), a biotechnology company developing novel cancer immunotherapies based on tumor-infiltrating lymphocyte (TIL) technology, today announced that it will webcast a business overview and update by Dr. Maria Fardis, PhD, MBA, Chief Executive Officer of lovance Biotherapeutics at the following upcoming investor conferences:

- **Rodman & Renshaw 19th Annual Global Investment Conference** in New York, NY on Monday, September 11, 2017 at 11:40 a.m. ET
- **2017 Cantor Fitzgerald Global Healthcare Conference** in New York, NY on Monday, September 25, 2017 at 8:00 a.m. ET

A live audio webcast of both presentations will be available by visiting the Investors section lovance Biotherapeutics' website at <http://ir.iovance.com/>. A replay of the webcast will be archived on lovance Biotherapeutics' website for 30 days following the presentation.

About lovance Biotherapeutics, Inc.

lovance Biotherapeutics, Inc. is a clinical-stage biotechnology company focused on the development of cancer immunotherapy products for the treatment of various cancers. The Company's lead product candidate is an adoptive cell therapy using tumor-infiltrating lymphocyte (TIL) technology being investigated for the treatment of patients with metastatic melanoma, recurrent and/or metastatic squamous cell carcinoma of the head and neck and recurrent and metastatic or persistent cervical cancer. For more information, please visit <http://www.iovance.com>.

Investor Relations Contact:

Sarah McCabe
Stern Investor Relations, Inc.
212-362-1200
sarah@sternir.com

Media Relations Contact:

Evan Smith/Kotaro Yoshida
FTI Consulting
212-850-5622/212-850-5690
evan.smith@fticonsulting.com
kotaro.yoshida@fticonsulting.com



lovance Biotherapeutics, Inc.